Condition
Ulcerative colitis news across medications, symptoms, monitoring, procedures, research, access, and daily life.
Page 2 of 40 · 1908 articles
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
This study reports that an optimized Cycas revoluta leaf extract reduced colon inflammation and markers of oxidative stress in a rat model of ulcerative colitis, suggesting it could be a source of bioactive compounds...
The article offers an Ayurvedic framework for understanding and managing ulcerative colitis that may interest patients seeking complementary approaches and clinicians exploring integrative care. It emphasizes dietary and...
Patients and clinicians may care because the investigational drug duvakitug reportedly sustained clinical and endoscopic benefits through 44 weeks in both ulcerative colitis and Crohn’s disease, which could represent a...
The paper identifies a metabolic pathway (HIF-1α–driven lactylation leading to ferroptosis) that may contribute to epithelial injury in ulcerative colitis and proposes quercetin as a candidate inhibitor—potentially...
This study identifies KCTD10 as a regulator of intestinal stem cell function and mucosal repair in experimental colitis, which could point to new mechanistic insights about why epithelial healing fails in some cases of...
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
The study identifies a redox–inflammasome pathway (Nrf2 linked to NLRP3/IL‑1β) relevant to UC and shows that sulforaphane can modulate this axis in intestinal epithelial cells, highlighting a potential therapeutic target...
People with ulcerative colitis may eventually have an oral small-molecule option that targets the TNF-α pathway instead of injectable biologics. Early-stage preclinical work suggests a new mechanism (allosteric MKK3...
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
If validated, differences in tissue QDPR could become a marker to help differentiate UC from CD and to indicate mucosal antioxidant/repair status, which may be relevant for disease monitoring and research into new...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Research and...
New Phase 2b maintenance data suggest a novel anti‑TL1A antibody may provide sustained symptom relief and mucosal improvement for some people with moderate-to-severe UC or CD — outcomes that matter because durable...
Early Phase 1b results suggest PALI-2108 may produce rapid improvements on endoscopy and calprotectin in very small Crohn’s and UC cohorts, which could matter if later trials confirm benefit and safety. The findings are...
Early-phase data suggest PALI-2108 reaches the ileum and colon and produced rapid reductions in endoscopic inflammation and fecal calprotectin in small Phase 1b cohorts—results that could matter if confirmed in larger...
If confirmed in later trials, a new TL1A‑targeting antibody could add a novel mechanism for patients with UC or Crohn’s who do not respond adequately to current therapies. Durable clinical and endoscopic responses over...
This trial is testing a novel stem-cell infusion approach aimed at treating Crohn’s disease and ulcerative colitis, so people with IBD may be interested in emerging cell-therapy options and safety data. Phase 1 studies...
An oral biologic study could offer a new treatment approach for people with moderate–severe ulcerative colitis; the trial is evaluating safety and multiple measures of disease activity including endoscopy and histology.
This preclinical study suggests a plant extract reduced inflammation and oxidative stress in a mouse model of ulcerative colitis and proposes molecular targets — an early step toward potential new treatments or research...
Biomarkers of gut barrier integrity and oxidative stress could reveal hidden inflammation, help predict disease progression, and indicate likely treatment response—steps toward more personalized IBD care.
Researchers identified a plant-derived compound that reduced inflammation, oxidative stress, and gut dysbiosis in a mouse model of ulcerative colitis; this could point to new mechanistic leads for future therapies...
An unusual craving to smell non-food substances (desiderosmia) can be a clue to severe iron deficiency anaemia and may point to undiagnosed inflammatory bowel disease in adolescents. Recognising this sign could speed...
The paper points out that reused patient records and preprocessing choices can change how well gene-expression models appear to predict infliximab response. That matters because such biases could mislead researchers and...
The review identifies PPARγ as a key molecular hub in ulcerative colitis and compiles preclinical evidence that natural compounds can modulate PPARγ-related networks—suggesting possible new therapeutic directions that...
Patients on or considering infliximab may be interested because the paper identifies a possible molecular reason some people don’t respond and tests strategies that could, in principle, improve response to infliximab.
This preclinical study suggests clarithromycin may reduce colon inflammation in ulcerative colitis models and identifies Kv1.3 and the Th17/Treg balance as possible mechanisms — findings that could guide future...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Lipids in Health and Disease.
Updated treat-to-target recommendations affect how inflammation and symptoms are monitored and when treatments should be changed. Clear targets and timing help patients and clinicians make consistent, evidence-informed...
People with UC and their clinicians often consider infection risks when choosing biologic therapy. This study examines whether vedolizumab and anti‑TNF drugs differ in risk for C. difficile infection, a relevant...
This study looks directly at whether failing multiple biologic drugs before elective subtotal colectomy affects short-term surgical outcomes for people with ulcerative colitis — information that can help patients and...
Patients and clinicians worry isotretinoin might trigger flares in people with existing IBD. This study suggests that among patients with stable, well-controlled Crohn's or UC, isotretinoin did not generally worsen...
This review compiles preclinical evidence that propolis (a natural bee product) reduced inflammation and improved gut barrier and microbiota in animal models of colitis, so it may be a candidate for future clinical...
This preclinical study suggests a food-derived peptide formulation might reduce inflammation and improve intestinal barrier markers in lab and mouse models of ulcerative colitis, which could interest people exploring new...
This study identifies a compound that improved inflammation, barrier integrity, and microbiome/metabolite signatures in a mouse model of ulcerative colitis—areas that matter for symptom control and disease biology in...
This study highlights a potential microbiome–bile acid–immune pathway that could be relevant to ulcerative colitis and suggests a traditional herbal formula may influence that pathway in mice. Patients interested in...
A blood biomarker that predicts anti-TNF response could help people with IBD and their clinicians choose the right biologic sooner, avoiding ineffective treatment. This study reports that lower baseline serum oncostatin...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis and Research and clinical trials. The original article is from Przegla̜d Gastroenterologiczny.
People with ulcerative colitis may be interested because the study suggests a combined probiotic approach could strengthen gut bacteria functions linked to a protective metabolite (spermidine) and reduce colitis-like...
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
Early antibody signatures could allow earlier identification of people at higher risk for Crohn’s disease or ulcerative colitis, which might eventually enable closer monitoring or preventative research.
This preclinical study identifies a parasite-derived fluid that reduced inflammation, oxidative stress, and microbiome disruption in a mouse model of ulcerative colitis and in intestinal cells, pointing to possible new...
Overlap of EoE and IBD appears uncommon but more frequent than in the general population and is linked to more allergic disease and higher steroid exposure without clearer increases in esophageal scarring. That may...
The study links lower vitamin D and higher TNF‑alpha with greater UC severity and with each other, suggesting these measurable biomarkers may reflect inflammation in ulcerative colitis.
If validated, antibody-based signals found years before symptoms could allow earlier risk identification and research into why immune responses precede IBD. That may matter for patients and clinicians interested in early...
A pediatric label for Omvoh could make an additional biologic option available for children with moderate-to-severe ulcerative colitis who respond to treatment. Trial results reported one-year remission among responders,...
Firsthand accounts show the real-life impact of ulcerative colitis on daily life, schooling, and mental health. Stories about surgery and ostomy reversal can help reduce stigma and highlight the importance of peer...
Cure8 found this source from fiercepharma.com, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Mirikizumab. Open the original article for the full...
The study suggests a colon-targeted herbal treatment altered metabolic and immune pathways and reduced inflammation in a rat model of ulcerative colitis, which could point to new therapeutic approaches to explore for UC...
